CRISPR Therapeutics is selling for under 40.80 as of the 23rd of January 2025; that is No Change since the beginning of the trading day. The stock's last reported lowest price was 40.8. CRISPR Therapeutics has more than 67 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 24th of December 2024 and ending today, the 23rd of January 2025. Click here to learn more.
Our tools can tell you how much better you can do entering a position in CRISPR Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.
Did you try this?
Run Financial Widgets Now
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
When running CRISPR Therapeutics' price analysis, check to measure CRISPR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CRISPR Therapeutics is operating at the current time. Most of CRISPR Therapeutics' value examination focuses on studying past and present price action to predict the probability of CRISPR Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CRISPR Therapeutics' price. Additionally, you may evaluate how the addition of CRISPR Therapeutics to your portfolios can decrease your overall portfolio volatility.